scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call on November 9, 2022, at 4:30 p.m. ET to discuss third-quarter financial results and provide a business update. The call will be accessible via phone or through an audio webcast. The company focuses on optimizing infused therapies to enhance patient care and reduce healthcare costs, with key programs on subcutaneous, self-administered treatments for heart failure and infectious diseases.

Positive

• Focus on developing self-administrable intravenous treatments that may improve patient outcomes.
• Potential for reduced healthcare costs through innovative product solutions.

Negative

• None.

BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals’ management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 9, 2022, to discuss third quarter financial results and provide a business update.

Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13732796. The live webcast and replay of the conference call can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com

FAQ

What is the date of scPharmaceuticals' third quarter financial results conference call?

The conference call is scheduled for November 9, 2022, at 4:30 p.m. ET.

How can I access the scPharmaceuticals conference call?

You can access the conference call by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13732796.

What does scPharmaceuticals focus on developing?

scPharmaceuticals focuses on developing products that optimize the delivery of infused therapies and improve patient care.

What are the main therapeutic areas for scPharmaceuticals?

The company primarily targets heart failure and infectious diseases with its lead programs.